NDA 020189 · Mylan Speciality Lp
Felbatol
Felbamate · Oral · Anti-epileptic Agent
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Aug 31, 2012 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1993
Jul 29, 1993
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
0 Phase 3, 0 recruiting
FAERS reports
1,779
1,266 serious, 89 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING 1. APLASTIC ANEMIA THE USE OF FELBATOL ® (felbamate) IS ASSOCIATED WITH A MARKED INCREASE IN THE INCIDENCE OF APLASTIC ANEMIA. ACCORDINGLY, FELBATOL ® SHOULD ONLY BE USED IN PATIENTS WHOSE EPILEPSY IS SO SEVERE THAT THE RISK OF APLASTIC ANEMIA IS DEEMED ACCEPTABLE IN LIGHT OF THE BENEFITS CONFERRED BY ITS USE (SEE INDICATIONS ). ORDINARILY, A PATIENT SHOULD NOT BE PLACED ON AND/OR CONTINUED ON FELBATOL ® WITHOUT CONSIDERATION OF APPROPRIATE EXPERT HEMATOLOGIC CONSULTATION. AMONG FELBATOL ® TREATED PATIENTS, APLASTIC ANEMIA (PANCYTOPENIA IN THE PRESENCE OF A BONE MARROW LARGELY DEPLETED OF HEMATOPOIETIC PRECURSORS) OCCURS AT AN INCIDENCE THAT MAY BE MORE THAN A 100 FOLD GREATER THAN THAT SEEN IN THE UNTREATED POPULATION (I.E., 2 TO 5 PER MILLION PERSONS PER YEAR). THE RISK OF DEATH IN PATIENTS WITH APLASTIC ANEMIA GENERALLY VARIES AS A FUNCTION OF ITS SEVERITY AND ETIOLOGY;...
What it is approved for
From the label in effect Aug 15, 2025.
INDICATIONS AND USAGE Felbatol ® is not indicated as a first line antiepileptic treatment (see Warnings ). Felbatol ® is recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk and has provided written acknowledgment, Felbatol ® can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.
Mechanism: Mechanism of Action The mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. Felbamate is effective in mice and rats in the maximal electroshock test, the subcutaneous pentylenetetrazol seizure test, and the subcutaneous picrotoxin seizure test. Felbamate also exhibits anticonvulsant activity against seizures induced by intracerebroventricular administration of glutamate in rats and N-methyl-D,L-aspartic acid in mice. Protection...
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 29, 1993 Original approval · Type 1 - New Molecular Entity · priority review Healthcare Professional Sheet
3 products under this application
- FELBATOL · FELBAMATE 600MG/5ML · SUSPENSION, ORAL · Discontinued · TE AB
- FELBATOL · FELBAMATE 400MG · TABLET, ORAL · Prescription · TE AB
- FELBATOL · FELBAMATE 600MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Felbamate" as an intervention, any sponsor and status, largest first.
Oslo University HospitalAcademic, hospital or other
NCT00552526 · 60 participants (planned) · Start Nov 2007 · Primary completion Jan 2011
Drug: Antiepileptic drug (AED) · For: Epilepsy; Mental Retardation
Sites: Oslo, Norway
National Institute of Mental Health (NIMH)NIH
NCT00034229 · 52 participants · Start Apr 2002
Drug: Felbamate · For: Bipolar Disorder
Sites: Bethesda, Maryland
- Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade GliomaCompleted
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
NCT00404248 · 35 participants · Start Jan 2007 · Primary completion Jun 2009
Drug: terameprocol · For: Brain and Central Nervous System Tumors
Sites: Birmingham, Alabama; Tampa, Florida; Atlanta, Georgia · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- seizure364
- drug ineffective263
- off label use134
- convulsion124
- somnolence114
- condition aggravated92
- fatigue87
- drug interaction73
- vomiting72
- toxicity to various agents71
- generalised tonic-clonic seizure68
- diarrhoea61
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 7 |
| 2006 | 23 |
| 2007 | 18 |
| 2008 | 11 |
| 2009 | 15 |
| 2010 | 30 |
| 2011 | 38 |
| 2012 | 73 |
| 2013 | 77 |
| 2014 | 98 |
| 2015 | 128 |
| 2016 | 113 |
| 2017 | 91 |
| 2018 | 104 |
| 2019 | 128 |
| 2020 | 155 |
| 2021 | 163 |
| 2022 | 119 |
| 2023 | 83 |
| 2024 | 111 |
| 2025 | 128 |
| 2026 | 56 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Felbatol (Felbamate)
2024 spending
$5.7M
Beneficiaries
237
1,837 claims
Per beneficiary
$23,913
$15.52 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $10,001,936 |
| 2021 | $10,012,244 |
| 2022 | $9,457,663 |
| 2023 | $7,319,135 |
| 2024 | $5,667,454 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force.
Tomson T, Battino D, Bromley R, et al. · Epileptic Disord 2022 · Systematic Review
- Anticonvulsant drug hypersensitivity.
Galindo PA, Borja J, Gómez E, et al. · J Investig Allergol Clin Immunol 2002 · Clinical Trial, Comparative Study
- Treatment of Lennox-Gastaut syndrome.
Hancock EC, Cross JH · Cochrane Database Syst Rev 2013 · Research Support, Non-U.S. Gov't, Systematic Review
- Felbamate in the treatment of Lennox-Gastaut syndrome.
Jensen PK · Epilepsia 1994 · Clinical Trial, Randomized Controlled Trial
- Anti-seizure medications for Lennox-Gastaut syndrome.
Brigo F, Jones K, Eltze C, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Felbamate as add-on therapy.
Li LM, Nashef L, Moriarty J, et al. · Eur Neurol 1996 · Clinical Trial, Controlled Clinical Trial
Sponsor: Mylan Speciality Lp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.